asenapine

BH3 interacting domain death agonist ; Homo sapiens







11 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 29170943 Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review. 2018 Apr 2
2 30122926 Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight. 2018 2
3 27821210 Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. 2017 Aug 2
4 28814871 Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study. 2017 3
5 26496015 Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. 2016 Jan 15 5
6 27271087 Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. 2016 Jul 1
7 22877962 Asenapine for elderly bipolar manic patients. 2013 Feb 15 1
8 22454251 Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. 2012 Jul 1
9 27121455 Asenapine Safety, Tolerability, and Pharmacokinetics After Single and Multiple Doses in Healthy Volunteers. 2012 Oct 1
10 20520283 Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. 2010 Apr 1
11 19840150 Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. 2009 Dec 4